GH-release research
3Human infusion studies measured hormone responses.
What does it do?
Selective ghrelin-receptor agonist with human GH-response research. Community sleep, recovery and body-composition goals have substantially weaker direct evidence.
Approved & studied uses
Postoperative bowel recovery research
1A controlled trial evaluated meal tolerance after bowel resection.
Community uses Reported, unvalidated
GH/IGF-1
13Hormone-response research.
Body composition and bone
13Muscle, fat and density claims extrapolate from GH biology.
Sleep and recovery
13Community reports, not established clinical indications.
Postoperative gut recovery
13Randomized human trial did not demonstrate efficacy over placebo.
Reasons people report using it; these do not establish benefit.13
Evidence limits
View research →Controlled evidence for community sleep, longevity and bodybuilding claims remains insufficient.1
1 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.
Evidence definitions →Key safety information
All risks →Serious-event reports
FDA notes serious events, including deaths, in IV research; this does not prove causation.2
No FDA-approved therapeutic product identified.
Molecular information
Amino-acid sequence
- 1
- 2
- 3
- 4
- 5
Residue count only · sequence not verified4
An exact sequence has not been verified for this formulation.
Length5 amino acids
Molecular weight · Da711.9 Da
Formula, sequence notation & identity
Molecular formulaC38H49N9O54
Ghrelin-receptor agonist pentapeptide.
Formula is the peptide, not an acetate salt or blend.
Pep-Pedia identity details
5 amino acids · 711.85 Da
Aib-His-D-2-Nal-D-Phe-Lys-NH₂Reference description; checked chemical identity above takes precedence when available.13
Pharmacokinetics
How long does it stay in the body?
Human data
Reported half-lifeApproximately 2 hours (intravenous)3
Route / formulation15-minute intravenous infusion
50%of reference level
Illustrative model using reported human data.
About 3% remaining after 10 h
Five half-lives in this simplified model. This is not a prediction of when effects stop.
Evidence and model details
Terminal human half-life from an IV dose-escalation study. It does not establish absorption or half-life for subcutaneous retail products.
Population: Healthy male volunteers
100 × 2−time / half-life. Time zero is a reference level, not the moment of administration. Absorption, repeated dosing, metabolites and clinical effects are not modeled. Five half-lives leaves 3.125%, not zero. This curve cannot determine a dosing interval.
Unverified reference estimateNot independently confirmed
Reference half-life2 hours12
Route / formulationSource page: Injectable. Exact PK route not verified.
This value is reported by a secondary reference. The stated attribution has not been independently verified as a route- and formulation-matched human PK measurement.
50%of reference level
Illustrative scenario using an unverified reference estimate.
About 3% remaining after 10 h
Five half-lives in this estimated model. This is not a prediction of when effects stop.
Evidence and model details
Population: Not established by the reference estimate
Source’s stated attribution: Raun et al. 1998
Source’s reported peak time: 40 min. This has not been independently confirmed and is not used in the elimination curve.
100 × 2−time / half-life. Time zero is a reference level, not the moment of administration. Absorption, repeated dosing, metabolites and clinical effects are not modeled. Five half-lives leaves 3.125%, not zero. This curve cannot determine a dosing interval.
What to expect
Study outcomes
Primary outcome not improved
Meal tolerance occurred at median 25.3 hours versus 32.6 with placebo; difference was not statistically significant (P=0.15).1
GH response is measurable
IV dosing stimulated a transient GH response; this is not evidence of anti-aging benefit.3
Reported timelines
Reference & communityWeeks 1–2; 2–4; 4–12
Source reports sleep, recovery then composition changes; not validated outcomes.13
These are reported timelines, not a prediction of your response.
Community poll 10 topics · Pep-Pedia snapshot
Voluntary, unverified reports. These percentages do not measure effectiveness or safety.
Experience
Number of responses to this question: not disclosed.
Duration of use
The source hides 3 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Age range
The source hides 2 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Gender
Number of responses to this question: not disclosed.
Primary goal
The source hides 2 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Effectiveness
The source hides 8 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Side effects
The source hides 17 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Dosage frequency
The source hides 10 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Would recommend
The source hides 2 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
How discovered
The source hides 4 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Source & limitations
The source displays “1335 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.
- Voluntary self-reports from Pep-Pedia visitors; identity, treatment, outcomes and timing are unverified. These data are not efficacy or safety estimates.
- The source displays a profile-wide response label, not a confirmed unique participant count. It stays unchanged across questions. Question-specific denominators and absolute option counts are not exposed.
- Only the top five categories are displayed for some questions. Extra categories are retained as an undisplayed-category count; their labels and percentages are unavailable.
- Displayed percentages are rounded. They may not total 100%, especially where categories are hidden.
- This is a dated snapshot, not a live survey or current recommendation.
Protocols
Doses & schedules
Compare purpose, amount, route, frequency, and duration.
Source corrections
Interaction labels are reference claims, not combination-safety findings.
Route
Scroll to compare all columns →
| Route | Dose | Frequency | Goal / evidence | Duration | References |
|---|---|---|---|---|---|
| IVIntravenous infusion | 0.03 mg/kg | Twice daily | Postoperative ileusHuman study | Postoperative days 1–7 or hospital discharge | 1 |
Population Bowel-resection patients; 114 in the efficacy analysis Context Hospital study; no significant improvement in the primary endpoint. | |||||
| SubQ | 200 mcg | 1x daily before bed | General Health & LongevityReference report | 3-6 months | 13 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Interaction labels are reference claims, not combination-safety findings. Source tabs Injectable | |||||
| SubQ | 250-300 mcg | 2x daily (morning, pre-workout) | Body CompositionReference report | 3-6 months | 13 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Interaction labels are reference claims, not combination-safety findings. Source tabs Injectable | |||||
| SubQ | 200-250 mcg | 2-3x daily (morning, pre/post workout) | Athletic PerformanceReference report | 3-6 months | 13 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Interaction labels are reference claims, not combination-safety findings. Source tabs Injectable | |||||
| SubQ | 200 mcg | 1x daily 30min before bed | Sleep & RecoveryReference report | 3-6 months | 13 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Interaction labels are reference claims, not combination-safety findings. Source tabs Injectable | |||||
| SubQ | 200-250 mcg | 1-2x daily (morning, bedtime) | Anti-Aging ProtocolReference report | 3-6 months | 13 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Interaction labels are reference claims, not combination-safety findings. Source tabs Injectable | |||||
No protocols match these filters.
Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.
Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.
Injectable
- Use period
- 3-6 months
- Break
- 1-2 months
Reported timing
Empty stomach, bedtime optimal for sleep benefits
Side effects & safety
Serious-event reports
FDA notes serious events, including deaths, in IV research; this does not prove causation.
2Route uncertainty
FDA identifies insufficient safety information for other injectable routes.
2Peptide quality
FDA flags immunogenicity concerns related to aggregation or impurities.
2Unknown chronic benefit/risk
Pregnancy, lactation and active cancer lack appropriate safety evidence.
Reported effects
Hunger and injection reactions; unusual swelling, fatigue or sleep disturbance needs assessment.
Cycling
Source's 3–4-month desensitization claim is not a validated safe-use rule.
Not a complete safety screen. Discuss health decisions with a qualified clinician.
Combinations & interactions
8 entriesCheck cautions and reported pairings. A compatibility claim does not establish that a combination is safe.
GHRP-2
Avoidance reportedOverlapping receptor action.13
Reference report · Pep-Pedia label: Avoid CombinationGHRP-6
Avoidance reportedOverlapping receptor action.13
Reference report · Pep-Pedia label: Avoid CombinationTesamorelin
Caution reportedPossible excessive GH/IGF-1.13
Reference report · Pep-Pedia label: Monitor CombinationCJC-1295
Unverified pairingComplementary receptor claim; formulation matters.13
Reference report · Pep-Pedia label: SynergisticBPC-157
Unverified pairingRepair/GH-receptor hypothesis.13
Reference report · Pep-Pedia label: SynergisticTB-500
Unverified pairingUntested recovery pairing.13
Reference report · Pep-Pedia label: CompatibleSermorelin
Unverified pairingGHRH-class hormone-response extrapolation.13
Reference report · Pep-Pedia label: SynergisticCJC-1295, sermorelin or other GH-axis agents
Not establishedThe cited human ipamorelin studies do not establish the safety or benefit of these combinations.31
Research contextNo matching interactions. Try another name or filter.
Reconstitution calculator
Enter your peptide amount and container size. Get a volume and a simple measurement scale.
Suggested final volume mL
Estimated water to add≈ mL
For dry powder, assuming negligible volume displacement. Use bacteriostatic water only if the formulation specifies it.
1 pen unit (one dial step)=
Amounts below are total blend mass. Ingredient amounts are listed separately.
| Pen units | Amount | Volume |
|---|
Ingredients per unit
Other simple scales
Convert a specific amount
Enter an amount to calculate its volume and device setting.
Calculation & assumptions
The suggestion favors a simple 1, 2, or 5 × power-of-ten amount per unit, then the largest final volume that fits. It does not choose a dose or a biologically suitable concentration.
The water estimate applies only to dry powder and assumes negligible powder displacement. Final solution volume, specified diluent, solubility, stability, sterility, cartridge compatibility, and working fill limits must be established separately. No allowance is made for priming or transfer losses.
V2 measurement specification ↗Bacteriostatic water: formulation instructions ↗Reconstitution
The hospital IV protocol does not establish a retail subcutaneous reconstitution method.1
Missing formulation details
A transferable diluent volume, storage period and stability specification were not verified.1
Reference preparation details
Reported handling information, not a validated formulation or instruction to prepare an injectable product.
Injectable
Pep-Pedia describes preparation for this route; product-specific stability has not been independently verified.
- Solvents mentioned
- Bacteriostatic water
- Reported parameters
- Reported post-preparation interval: 28 days. · The source specifies refrigeration after preparation.
The source describes gentle mixing and avoiding vigorous shaking.
Appearance & documentation
Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.
Reported appearanceWhite, Fine Crystalline PowderReported appearanceClear Solution After ReconstitutionReported appearanceMild Hunger ResponseReported variationSlight Drowsiness (Bedtime Doses)Reported concernYellow or Discolored PowderReported concernNo Physiological Response
13Vial sizes
Packaging examples, not a market survey. Approved and research products are not interchangeable.
Storage after mixing
Reconstituted research vials
Pep-Pedia reports these handling limits after mixing. They are not validated stability or sterility limits for your vial.
Full storage notes from Pep-Pedia
13Refrigerate 2-8°C, use within 28 days after reconstitution
Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.
Pen & syringe measurements Scales, capacity & references
Pen & syringe measurements
Device units measure volume. Concentration determines the amount in mg.
1 notch = 0.01 mL
Documented 1-unit V2 models
- One dial increment
- 1 unit
- Cartridge capacity
- 3 mL
- Maximum setting
- 60 units · 0.60 mL
Use the numbered dose window. Whole-unit settings only; confirm the specification for your exact model.
1 unit = 0.01 mL
100 units = 1 mL
- 10 units
- 0.10 mL
- 30-unit capacity
- 0.30 mL
- 50 / 100-unit capacity
- 0.50 / 1 mL
Read the printed unit scale. A small line may represent 0.5, 1, or 2 units depending on the syringe.
Use the mL scale
mL syringes and calibrated pipettes
- 0.01 mL
- 10 µL
- 0.10 mL
- 100 µL
- Amount
- mL × mg/mL
Drops, sprays and other pen clicks need their own verified volume per increment. They have no universal conversion.
3 mL is cartridge capacity. It does not mean you must prepare or load 3 mL. The original vial and the pen cartridge are different containers. This reference compares measurement scales; it does not establish product or route compatibility.
Device references
AVERON V2 specifications ↗SilverLeaf V2 unit reference ↗FDA: syringe unit conversions ↗Specifications checked October 12, 2026.Research findings
Limited human dataSource context
Interaction labels are reference claims, not combination-safety findings.
Compound identity & other names
A peptide studied for growth-hormone release and postoperative bowel recovery. Human hospital research does not establish the sleep, physique or recovery benefits claimed for community subcutaneous use.
Other names: Ipa · Ipamorelin acetate
No FDA-approved therapeutic product identified.
How it may work
Stimulates pituitary GH secretion; selectivity findings do not guarantee absence of cortisol, prolactin or glucose effects in every setting.13
The bowel-recovery trial did not show a significant primary benefit
In a phase 2 postoperative trial, 114 participants comprised the safety/modified intention-to-treat population. Median time to a tolerated meal was 25.3 versus 32.6 hours with placebo; the difference was not statistically significant (p=0.15).
1Route and population limit the inference
The trial used IV infusions in hospital patients after bowel resection. It cannot validate an at-home subcutaneous regimen for sleep or body composition.
1Source checks & newer research
Randomized proof-of-concept study of ipamorelin for postoperative ileus
In 114 analyzed bowel-resection patients, time to tolerated meal was 25.3 versus 32.6 hours (p=0.15); key and secondary efficacy outcomes did not differ significantly from placebo. This does not test community body-composition use.
Human randomized phase 2 trial14Research areas and evidence gaps
GH-release research. Human infusion studies measured hormone responses.3
Postoperative bowel recovery research. A controlled trial evaluated meal tolerance after bowel resection.1
- Controlled evidence for community sleep, longevity and bodybuilding claims remains insufficient.
- Effects and risks of combinations with GHRH analogues are not established by the trial summarized here.
Community reports Unvalidated
Pep-Pedia describes sleep and recovery benefits, with repeated or bedtime use. These claims are not established by the postoperative trial.5
A secondary protocol description, not a clinical recommendation or a representative survey. Dose, product identity, other compounds and outcome reporting are not independently verified.
Search coverage and review status
No additional 2025–2026 peer-reviewed efficacy trial of this exact product was identified in this targeted check. Earlier evidence and unresolved listed references are retained.
- Checked
- 2026-10-12
- Search
- "ipamorelin" 2025 2026 trial site:pubmed.ncbi.nlm.nih.gov
- Catalog
- Pep-Pedia ↗ · 5 listed references retained
- Targeted search, not an exhaustive systematic review.
- Bibliography-only entries are retained for traceability and are not treated as verified findings.
AI-prepared summaries. Independent medical editorial review is pending.
References
Original sources and review status. Open a reference to read its summary.
1Ipamorelin for postoperative ileus: randomized phase 2 studyReview status not recorded
AI-PREPARED SUMMARY
IV treatment did not significantly shorten time to first tolerated meal versus placebo (25.3 vs 32.6 hours; p=0.15).
The bowel-recovery trial did not show a significant primary benefit
In a phase 2 postoperative trial, 114 participants comprised the safety/modified intention-to-treat population. Median time to a tolerated meal was 25.3 versus 32.6 hours with placebo; the difference was not statistically significant (p=0.15).
Route and population limit the inference
The trial used IV infusions in hospital patients after bowel resection. It cannot validate an at-home subcutaneous regimen for sleep or body composition.
2FDA: ipamorelin acetate safety concernsReview status not recorded
AI-PREPARED SUMMARY
FDA flags limited injectable safety data and serious events reported during IV research.
3Human ipamorelin pharmacokinetic/pharmacodynamic studyReview status not recorded
AI-PREPARED SUMMARY
Healthy male volunteers received 15-minute IV infusions. Terminal half-life was two hours; GH effects were transient.
4PubChem: ipamorelin chemical identityReview status not recorded
AI-PREPARED SUMMARY
Records the defined pentapeptide, formula and molecular weight.
5Pep-Pedia: ipamorelin — community referenceCommunity source checked
AI-PREPARED SUMMARY
Accessed October 12, 2026. Reports commonly discussed protocols; these schedules are unvalidated descriptions, not evidence of safety or efficacy.
6Research catalog: labeled vial examplesCatalog checked
AI-PREPARED SUMMARY
Catalog lists standalone 2, 5 and 10 mg research vials. These are seller label examples, not verified contents, market-frequency estimates or supplier endorsements.
7Safety and Tolerability Analysis (2023)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Broad long-term tolerability and hormonal-safety claims are made without an identifiable study link or sample size.
Reported population / model
Multi-center study
Reported study details
Various doses · Long-term safety assessment
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
8Athletic Performance Study (2022)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Athletic recovery, protein synthesis and inflammation benefits are claimed, but the card gives no linked trial or participant count.
Reported population / model
Athletes
Reported study details
200-300mcg daily · Performance and recovery markers
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
9Sleep Quality Research (2021)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Improved latency and slow-wave sleep are claimed over six weeks; the primary trial is not linked.
Reported population / model
Adults with sleep issues
Reported study details
200mcg before bed · 6-week study
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
10Body Composition Clinical Trial (2020)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The source claims better lean mass, fat percentage and bone density in older adults; sample size, comparator and original report are missing.
Reported population / model
Adults 45+
Reported study details
250mcg daily · 12-week study · Lean mass and bone density
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
11Growth Hormone Stimulation Study (2019)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The source describes GH peaks 30–60 minutes after injection without cortisol/prolactin effects; the unlinked trial requires verification.
Reported population / model
Adults
Reported study details
200mcg daily · 8-week study · Consistent GH elevation
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
12Pep-Pedia: Ipamorelin — reported pharmacokineticsReference estimate; not independently verified human PKCommunity source checked
AI-PREPARED SUMMARY
Lists a half-life of 2 hrs and a peak time of 40 min. Stated attribution: Raun et al. 1998. This value is reported by a secondary reference. The stated attribution has not been independently verified as a route- and formulation-matched human PK measurement. Five half-lives is not complete clearance, and the source’s “cleared” value is not used as a measured endpoint.
Secondary reference page checked; the underlying quantitative claim is not independently confirmed. · Checked 2026-10-12
13Pep-Pedia: Ipamorelin — route-specific referenceReference page checked; underlying claims require separate verification.Community source checked
AI-PREPARED SUMMARY
Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.
Content coverage audit · Checked 2026-10-12
14Randomized proof-of-concept study of ipamorelin for postoperative ileusPrimary source checked
AI-PREPARED SUMMARY
In 114 analyzed bowel-resection patients, time to tolerated meal was 25.3 versus 32.6 hours (p=0.15); key and secondary efficacy outcomes did not differ significantly from placebo. This does not test community body-composition use.
Randomized proof-of-concept study of ipamorelin for postoperative ileus
In 114 analyzed bowel-resection patients, time to tolerated meal was 25.3 versus 32.6 hours (p=0.15); key and secondary efficacy outcomes did not differ significantly from placebo. This does not test community body-composition use.
Additional primary-source check · Checked 2026-10-12